跳至主要内容
临床试验/ACTRN12612000635864
ACTRN12612000635864已完成2 期

Phase II of a novel telehealth-mediated nurse-led intervention to increase oral cancer therapy adherence amongst people with Chronic Myeloid Leukaemia (CML)(REMIND study)

Australasian Leukaemia and Lymphoma Group0 个研究点目标入组 40 人开始时间: 2012年6月14日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Educational / counselling / training
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1.a confirmed diagnosis of CML in the chronic phase with no signs and symptoms of progression to the accelerated or blastic phases as per investigator’s opinion
  • 2.no evidence of Imatinib resistance (as determined by the site investigator)
  • 3.Currently taking or about to commence treatment with Imatinib
  • 4.over 18 years
  • 5.proficient in English
  • 6.able to give informed consent.
  • 7.An ECOG performance status score of 2 or less at Screening

排除标准

  • 1.Demonstrated cognitive or psychological difficulties that would preclude study participation as defined by the treatment team’s cognitive and / or psychiatric assessment or patient’s disclosed medical history
  • 2.Too unwell to participate in the study as determined by the patient’s treatment team.

研究者

发起方
Australasian Leukaemia and Lymphoma Group

相似试验